Not Signed In -
Warts, Genital |
Anal Warts |
Clinical Trial: An up to Twelve Week Safety and Efficacy Study with a Topical Gel to Treat Common Warts in Pediatric Subjects
This study is currently recruiting patients.
|
Purpose
The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks.
A second purpose is to evaluate the safety of the drug.
| Condition | Intervention | Phase |
|---|---|---|
| Warts | Drug: Resiquimod | Phase II |
MedlinePlus related topics: Warts
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Single Blind, Dose Comparison, Single Group Assignment, Safety/Efficacy Study
Official Title: A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects
Secondary Outcomes: Partial clearance of treated common wart(s); Wart recurrence
Expected Total Enrollment: 84
Study start: March 2005; Expected completion: September 2006
Last follow-up: July 2006; Data entry closure: September 2006
Eligibility
Inclusion Criteria:
- Diagnosis of common wart(s)
- Ages between 3 to 11
Exclusion Criteria:
Location and Contact Information
Massachusetts
Massachusetts General Hospital-Dermatology Clinical Studies Unit, 275 Cambridge St., Professional Office Building 402, Boston, Massachusetts, 02114, United States; Recruiting
Alexa B Kimball, M.D., M.P.H., Principal Investigator
Alexa B Kimball, M.D., M.P.H, Principal Investigator, Massachusetts General Hospital-Dermatology Clinical Studies Unit
More Information
Record last reviewed: June 2005
Last Updated: June 30, 2005
Record first received: June 30, 2005
ClinicalTrials.gov Identifier: NCT00116662
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-07-05
email this page
print this page
bookmark this page
feedback on this page
